← All trials
NCT04730583
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jan 29, 2021
- Last posted
- May 27, 2021
- Enrollment
- 20
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Johns Hopkins UniversityCollaborator
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOfficial
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.